Patents Assigned to Wyeth
  • Multi composition stick product and a process and system for manufacturing same
    Patent number: 7073965
    Abstract: A multi-composition stick product, such as a lip balm, sun screen, deodorant, or glue stick. The multi-composition stick product including a stick composition molded in the container so as to contact the walls thereof and be advanceable or ejected therefrom. The stick composition includes a first composition and a second composition. The first and second compositions differ in at least one component, such as a medicament, colorant, fragrance, flavorant, sunscreen, preservative, conditioner, moisturizer, emollient, or surfactant. Furthermore the first and second compositions are arranged in a predetermined non-random pattern that is reproducible. Also described is the method and apparatus for manufacturing the multi-composition stick product.
    Type: Grant
    Filed: February 28, 2005
    Date of Patent: July 11, 2006
    Assignee: Wyeth
    Inventors: Jee Loon Look, Paul Joseph Cooper, Khawla Abdullah Abu-Izza, Joyce H. Wilson, Krishna P. Raman, Vincent Hon-Kin Li
  • 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands
    Patent number: 7074792
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: July 11, 2006
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Steven Edward Lenicek, Schuyler Adam Antane
  • Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-Benzodioxan
    Publication number: 20060148881
    Abstract: Compounds of the Formula I: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
    Type: Application
    Filed: March 10, 2006
    Publication date: July 6, 2006
    Applicant: Wyeth
    Inventors: Deborah Evrard, Uresh Shah, Gary Stack
  • Methods for identifying modulators of N-type ion channel inactivation
    Publication number: 20060148000
    Abstract: Methods and compositions for identifying compounds which disrupt the functional interaction of an intracellular receptor region of an a-subunit of a voltage gated ion channel and an amino-terminal inactivation region of an ion channel protein are disclosed. Compounds that disrupt the functional or binding interaction of these two regions have significant modulatory effects on ion channel activity, and thus are likely to be useful for treating and/or preventing a wide variety of diseases and pathological conditions associated with ion channel dysfunction. Such conditions include, for example, neurological disorders, cardiac diseases, metabolic diseases, tumor-driven diseases, and autoimmune diseases.
    Type: Application
    Filed: January 31, 2006
    Publication date: July 6, 2006
    Applicant: Wyeth
    Inventors: Kathleen Young, Kenneth Rhodes
  • 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands
    Publication number: 20060148831
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: March 3, 2006
    Publication date: July 6, 2006
    Applicant: Wyeth
    Inventors: Ronald Bernotas, Steven Lenicek, Schuyler Antane
  • 1,2,3,4,7,8-hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
    Patent number: 7071185
    Abstract: Compounds of Formula I or a pharmaceutically acceptable salt thereof are provided: where R1 through R7 are defined herein. The compounds of Formula I are 5HT2c agonists or partial agonists, and are useful for treating a variety of disorders.
    Type: Grant
    Filed: April 24, 2003
    Date of Patent: July 4, 2006
    Assignee: Wyeth
    Inventors: P. Sivaramakrishnan Ramamoorthy, Robert E. McDevitt
  • Estrogen replacement therapy
    Publication number: 20060142258
    Abstract: This invention relates to methods and pharmaceutical compositions for providing estrogen replacement therapy in penmenopausal, menopausal, and postmenopausal women through the continuous administration of conjugated estrogens.
    Type: Application
    Filed: February 8, 2006
    Publication date: June 29, 2006
    Applicant: Wyeth
    Inventor: James Pickar
  • Cyclothiocarbamate derivatives as progesterone receptor modulators
    Publication number: 20060142280
    Abstract: Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure: wherein R1, R2, R3, R4, R5, and Q1 are defined herein.
    Type: Application
    Filed: February 9, 2006
    Publication date: June 29, 2006
    Applicant: Wyeth
    Inventors: Puwen Zhang, Andrew Fensome, Eugene Terefenko, Lin Zhi, Todd Jones, James Edwards, Christopher Tegley, Jay Wrobel, Mark Collins
  • Platlet glycoprotein Ib alpha fusion polypeptides and methods of use thereof
    Publication number: 20060140935
    Abstract: The present invention provides compositions and methods for treating or preventing vascular-associated disorders.
    Type: Application
    Filed: October 24, 2005
    Publication date: June 29, 2006
    Applicant: Wyeth
    Inventors: Gray Shaw, Dianne Sako, Ravindra Kumar, Francis Sullivan, Tom McDonagh
  • 1-Heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
    Publication number: 20060142330
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: February 15, 2006
    Publication date: June 29, 2006
    Applicant: Wyeth
    Inventors: Ronald Bernotas, Steven Lenicek, Hassan Elokdah, David Li
  • Packaging of positive-strand RNA virus replicon particles
    Publication number: 20060141602
    Abstract: The invention generally relates to recombinant polynucleotides, positive-strand RNA virus (psRNAV) recombinant expression vectors, and packaging systems. The packaging systems are based on the expression of helper functions by coinfecting re-combinant poxvirus vectors comprising recombinant polynucleotides. Methods for obtaining psRNAV replicon particles using these packaging systems are disclosed. Immunogenic compositions and pharmaceutical formulations are provided that comprise replicon particles of the invention. Methods for generating an immune response or producing a pharmaceutical effect are also provided.
    Type: Application
    Filed: December 8, 2005
    Publication date: June 29, 2006
    Applicant: Wyeth Holdings Corporation
    Inventors: Gerald Kovacs, Nikolaos Vasilakis, Jacek Kowalski, Seema Gangolli, Timothy Zamb
  • Compositions and methods for treating rage-associated disorders
    Publication number: 20060140933
    Abstract: Fusion proteins comprising a Receptor for Advanced Glycation End Products Ligand Binding Element (RAGE-LBE) and an immunoglobulin element are disclosed. Also disclosed are fusion proteins comprising a RAGE-LBE and a dimerization domain. Also disclosed are nucleic acids encoding such fusion proteins and methods for using disclosed nucleic acids and proteins to, for example, treat RAGE-related disorders. Additional compositions and methods are also disclosed.
    Type: Application
    Filed: August 18, 2003
    Publication date: June 29, 2006
    Applicant: Wyeth and Imperial College Innovations Limited
    Inventors: Debra Pittman, Brian Clancy, Glenn Larsen, William Trepicchio, Fionula Brennan, Marc Feldmann, Brian John Foxwell, Jeffrey Feldman
  • Pyridinyl-methyl-ethyl cyclohexanecarboxamides as serotonergic agents
    Patent number: 7067518
    Abstract: A compound having 5-HT1A receptor activity, represented by the chemical formula wherein: Ar is 2-methoxyphenyl, 1H-indol-4-yl or 2,3-dihydro-1,4-benzodioxin-5-yl; R1 is 2-, 3- or 4-pyridyl; R2 is H or C1-6alkyl; R3 is H or C1-6alkyl; and R4 is H or methyl, or an optical isomer thereof, or a pharmaceutically acceptable salt of such a compound or optical isomer. The invention also includes compositions containing such a compound, as well as methods for using a compound of the invention.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: June 27, 2006
    Assignee: Wyeth
    Inventors: Lynne P. Greenblatt, Michael G. Kelly, Yvette L. Palmer
  • Substituted phenyl naphthalenes as estrogenic agents
    Patent number: 7067524
    Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10, are as defined in the specification, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: June 27, 2006
    Assignee: Wyeth
    Inventors: Richard E. Mewshaw, Richard J. Edsall, Cuijian Yang, Heather A. Harris, James C. Keith, Jr., Leo M. Albert, Eric S. Manas
  • Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
    Publication number: 20060135550
    Abstract: The present invention provides compounds of the following structure, wherein R1-R9, R15, and n are defined herein. These compounds are useful in treating neurological disorders or complications due to stroke or head injury, and as neuroprotective and neuroregenerative agents.
    Type: Application
    Filed: December 15, 2005
    Publication date: June 22, 2006
    Applicant: Wyeth
    Inventors: Edmund Graziani, Kevin Pong, Jerauld Skotnicki
  • Novel uses for estrogen beta agonists
    Publication number: 20060135574
    Abstract: This invention provides methods for treating cognitive diseases or disorders and symptoms thereof with estrogen beta selective agonists.
    Type: Application
    Filed: December 15, 2005
    Publication date: June 22, 2006
    Applicant: Wyeth
    Inventors: Mark Day, Heather Harris
  • Methods and systems for prognosis and treatment of solid tumors
    Publication number: 20060134671
    Abstract: The present invention provides methods, systems and equipment for the prognosis and treatment of renal cell carcinoma (RCC) or other solid tumors. Genes prognostic of clinical outcomes of a solid tumor can be identified according to the present invention. The expression profiles of these genes in peripheral blood mononuclear cells (PBMCs) of patients who have the solid tumor are correlated with clinical outcome of these patients. Examples of RCC prognosis genes are illustrated in Tables 2 and 3. These genes can be used as surrogate markers for predicting clinical outcome of an RCC patient of interest. These genes can also be used for the selection of a favorable treatment for an RCC patient of interest.
    Type: Application
    Filed: November 22, 2005
    Publication date: June 22, 2006
    Applicant: Wyeth
    Inventors: Michael Burczynski, Andrew Dorner, Natalie Twine, William Trepicchio, Donna Slonim, Andrew Strahs, Frederick Immermann
  • Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative,and inflammatory disorders
    Publication number: 20060135549
    Abstract: The present invention provides compounds of the following structure, wherein R1, R2, R4, R4?, R6, R7, and R15 are defined above: These compounds are useful in treating neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders. The compounds are therefore useful as neuroprotective and neuroregenerative, anti-proliferative, and anti-inflammatory agents.
    Type: Application
    Filed: December 15, 2005
    Publication date: June 22, 2006
    Applicant: Wyeth
    Inventors: Edmund Graziani, Kevin Pong, Jerauld Skotnicki
  • Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
    Patent number: 7064120
    Abstract: This invention provides novel substituted tricyclic pyridyl carboxamides which act as oxytocin receptor competitive antagonists, as well as methods of their manufacture, pharmaceutical compositions and methods of their use in treatment, inhibition, suppression or prevention of preterm labor, dysmenorrhea, endometritis, suppression of labor at term prior to caesarean delivery, and to facilitate antinatal transport to a medical facility. These compounds are also useful in enhancing fertility rates, enhancing survival rates and synchronizing estrus in farm animals; and may be useful in the prevention and treatment of disfunctions of the oxytocin system in the central nervous system including obsessive compulsive disorder (OCD) and neuropsychiatric disorders.
    Type: Grant
    Filed: April 10, 2002
    Date of Patent: June 20, 2006
    Assignee: Wyeth
    Inventors: Amedeo Arturo Failli, Jay Scott Shumsky, Thomas Joseph Caggiano, Joseph Peter Sabatucci, Kevin Anthony Memoli, Eugene John Trybulski
  • Variants of glycogen synthase kinase 3 and uses thereof
    Publication number: 20060127388
    Abstract: The present invention provides GSK3? variants, including splice variants expressed in bone or other tissues. These variants have a broad range of functional activity, from inhibiting the Wnt pathway to activating the pathway as dominant-negatives of the full-length GSK3?. These variants, as well as their modulators, can be used to treat diseases that involve GSK3? or its associated signaling pathways.
    Type: Application
    Filed: December 9, 2005
    Publication date: June 15, 2006
    Applicant: Wyeth
    Inventors: Michael Cain, Paul Yaworsky